Alaya.bio

Alaya.bio is a preclinical-stage biotechnology company developing in vivo CAR-T cell therapies. Its proprietary targeting polymeric nanoparticle platform delivers lentiviral vectors and other genetic payloads directly to circulating T cells, reprogramming them inside the body. The approach aims to replace complex ex vivo manufacturing with a scalable, injectable treatment platform for oncology and autoimmune diseases, while supporting broader gene-delivery partnerships.